80 completed, 25 unknown, 8 not yet recruiting, 5 recruiting. 69 Phase 1, 23 Phase 3, 16 Phase 4, 8 Phase 2, 5 Not applicable.
Follow HK inno.N Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tegoprazan-Aspirin Drug Interaction in Healthy Adult Male Volunteers Aspirin, Tegoprazan, Tegoprazan + Aspirin - Healthy Adult Male | Phase 1 | Not yet recruiting | HK inno.N Corporation | 34 | 2026-10-14 | 2026-10-01 |
| A Study to Evaluate Tegoprazan as a Diagnostic Tool for GERD Tegoprazan 50 mg, Placebo - GERD (Gastroesophageal Reflux Disease) | Phase 4 | Not yet recruiting | HK inno.N Corporation | 100 | 2026-09-01 | 2026-09-17 |
| A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia IN-207907 120 mg, IN-207907 240 mg, IN-207907 360 mg - Sarcopenia in Elderly | Phase 2 | Not yet recruiting | HK inno.N Corporation | 100 | 2026-09-01 | 2026-06-25 |
| Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke) Tegoprazan 50 mg, Placebo - Ischemic Stroke, Ischemic Stroke, Acute | Phase 3 | Recruiting | Hanyang University Guri Hospital | 1524 | 2026-01-26 | 2026-07-08 |
| A Study to Evaluate the Pharmacokinetics and Safety of IN-M00007 and IN-R00007 in Healthy Adult Volunteers IN-R00007, IN-M00007 - Healthy Volunteers | Phase 1 | Not yet recruiting | HK inno.N Corporation | 60 | 2026-01-01 | 2025-12-31 |
| A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers Tegoprazan, Naproxen, IN-M00002 - Healthy Volunteer | Phase 1 | Not yet recruiting | HK inno.N Corporation | 74 | 2025-12-27 | 2025-12-11 |
| Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone IN-B00009, Placebo - Diabetes (DM), Diabetes Mellitus Type 2 | Phase 3 | Not yet recruiting | HK inno.N Corporation | 110 | 2025-12-01 | 2025-12-29 |
| Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus IN-B00009, Placebo - Obesity &Amp; Overweight | Phase 3 | Not yet recruiting | HK inno.N Corporation | 300 | 2025-09-22 | 2025-09-25 |
| A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients IN-115314 Ointment 1%, IN-115314 Ointment 3%, IN-115314 Ointment placebo - Mild to Moderate Atopic Dermatitis | Phase 2 | Recruiting | HK inno.N Corporation | 162 | 2025-08-12 | 2026-09-09 |
| Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia Tegoprazan, Famotidine, Placebo - General Anesthesia | Phase 4 | Enrolling by invitation | Seok Kyeong Oh | 174 | 2025-07-23 | 2025-09-05 |
| Calorie Restricted Dietary Intervention in Type 2 Diabetes Patients With Obesity for Remission Contrave ER, Low-calorie meal box - Diabetes, Type 2, Obesity &Amp; Overweight | Phase 4 | Completed | Yeouido St. Mary's Hospital | 25 | 2025-07-01 | 2026-08-07 |
| This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants IN-114199 2.5mg or placebo, IN-114199 10mg or placebo, IN-114199 20mg or placebo - Chronic Idiopathic Constipation | Phase 1 | Not yet recruiting | HK inno.N Corporation | 80 | 2024-12-16 | 2024-12-17 |
| A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) Dual-combination therapy, Triple-combination therapy, Dexcom G7, Pasta - Type 2 Diabetes | Not applicable | Recruiting | Kyu Chang Won | 5950 | 2024-11-21 | 2025-04-24 |
| To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers IN-R00002, IN-G00002 - Non-valvular Atrial Fibrillation (NVAF) | Phase 1 | Active not recruiting | HK inno.N Corporation | 60 | 2024-08-16 | 2024-12-10 |
| PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects Tegoprazan 12.5mg, Tegoprazan 25mg, Famotidine 20mg - Healthy | Phase 1 | Unknown | HK inno.N Corporation | 36 | 2024-03-19 | 2024-03-27 |
| Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects Clopidogrel 75 mg, Tegoprazan 25 mg, Esomeprazole 20mg - Healthy | Phase 1 | Unknown | HK inno.N Corporation | 48 | 2023-12-05 | 2023-12-11 |
| Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients Adjuvant Chemotherapy | Recruiting | HK inno.N Corporation | 36 | 2023-09-25 | 2024-04-29 | |
| Aggressive Hydration With Lactated Ringer's Solution Versus Plasma Solution for the Prevention of Post ERCP Pancreatitis Plasma solution (4-hour aggressive hydration), Lactated Ringer solution (4-hour aggressive hydration), 8-hour aggressive hydration - Pancreatic Disease | Phase 4 | Completed | Do Hyun Park | 844 | 2023-06-19 | 2025-02-06 |
| A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn Tegoprazan, Esomeprazole - Gastroesophageal Reflux Disease | Phase 4 | Unknown | HK inno.N Corporation | 338 | 2023-03-24 | 2023-08-03 |
| An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients GERD (Gastroesophageal Reflux Disease) | Recruiting | HK inno.N Corporation | 5384 | 2023-03-07 | 2026-07-01 |
Showing 20 of 121. Sign in to see all of them.
Hypertension (7) · Diabetes Mellitus (6) · Gastroesophageal Reflux (4) · Hyperlipidemias (4) · Smallpox (4) · Diabetes Mellitus, Type 2 (3) · Essential Hypertension (3) · Breast Neoplasms (2) · Hand, Foot and Mouth Disease (2) · Hyperphagia (2) · Obesity (2) · Overweight (2) · Postoperative Nausea and Vomiting (2) · Altitude Sickness (1) · COVID-19 (1)
tegoprazan (27) · Amlodipine (9) · Esomeprazole (9) · Rosuvastatin Calcium (7) · Atorvastatin (6) · Lansoprazole (6) · candesartan cilexetil (6) · Amlodipine, Valsartan Drug Combination (4) · Clopidogrel (4) · Valsartan (4) · Clarithromycin (3) · Metformin (3) · Palonosetron (3) · Amoxicillin (2) · Bismuth (2)
South Korea (100) · Vietnam (1)
In-Jin Jang, MD, PhD (5) · Jae Gook Shin, MD, ph D (3) · Ji Young Park, PhD (3) · Min-Gul Kim (3) · In-Jin Jang (2) · In-Jin Jang, MD, Ph.D (2) · Jae-wook Ko, MD, PhD (2) · Kyun-Seop Bae, MD, Ph.D (2) · Min-Gul Kim, MD (2) · Myoung-don Oh, M.D. (2) · Sang Kil Lee, Ph.D (2) · Cheol-Young Park (1) · Dae Hee Kim, MD (1) · Dae Young Zang, MD, PhD (1)
PMID 17597266, PMID 20600480, PMID 22281018, PMID 24616593, PMID 25034618, PMID 25037960, PMID 25161160, PMID 27249416, PMID 27460100, PMID 29172403, PMID 30506495, PMID 33637332, PMID 34227708, PMID 34246485, PMID 35787943, PMID 35791797, PMID 37349841, PMID 37440779, PMID 38955368, PMID 39587796, PMID 39932678, PMID 40462641, PMID 41531249, PMID 42325011, PMID 42640715, PMID 42806494